Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jan 26;12(1):e0170842.
doi: 10.1371/journal.pone.0170842. eCollection 2017.

Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation

Ihdina Sukma Dewi  1 , Zsuzsanna Hollander  2   3 , Karen K Lam  2 , Janet-Wilson McManus  4 , Scott J Tebbutt  2   3   5   6 , Raymond T Ng  2   7 , Paul A Keown  8 , Robert W McMaster  9 , Bruce M McManus  2   3   6   10 , Olof Gidlöf  1 , Jenny Öhman  1
Affiliations
Free PMC article
Multicenter Study

Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation

Ihdina Sukma Dewi et al. PLoS One. .
Free PMC article

Abstract

Background: Identifying non-invasive and reliable blood-derived biomarkers for early detection of acute cellular rejection in heart transplant recipients is of great importance in clinical practice. MicroRNAs are small molecules found to be stable in serum and their expression patterns reflect both physiological and underlying pathological conditions in human.

Methods: We compared a group of heart transplant recipients with histologically-verified acute cellular rejection (ACR, n = 26) with a control group of heart transplant recipients without allograft rejection (NR, n = 37) by assessing the levels of a select set of microRNAs in serum specimens.

Results: The levels of seven microRNAs, miR-142-3p, miR-101-3p, miR-424-5p, miR-27a-3p, miR-144-3p, miR-339-3p and miR-326 were significantly higher in ACR group compared to the control group and could discriminate between patients with and without allograft rejection. MiR-142-3p and miR-101-3p had the best diagnostic test performance among the microRNAs tested. Serum levels of miR-142-3p and miR-101-3p were independent of calcineurin inhibitor levels, as measured by tacrolimus and cyclosporin; kidney function, as measured by creatinine level, and general inflammation state, as measured by CRP level.

Conclusion: This study demonstrated two microRNAs, miR-142-3p and miR-101-3p, that could be relevant as non-invasive diagnostic tools for identifying heart transplant patients with acute cellular rejection.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Serum levels of microRNAs in heart transplant patients.
The levels of seven microRNAs were significantly higher in heart transplant patients with allograft rejection (ACR, n = 26) compared to the patients without rejection (NR, n = 37). Data is shown as mean ± SEM. Statistical analysis was performed with Student’s t-test. *P<0.05; **P<0.01.
Fig 2
Fig 2. Receiver Operator Characteristic (ROC) analysis.
Patients with and without acute cellular rejection could be discriminated by miR-142-3p (AUC = 0.78, CI95% = 0.67 to 0.89), miR-101-3p (AUC = 0.75, CI95% = 0.62 to 0.87), miR-424-5p (AUC = 0.73, CI95% = 0.60 to 0.86), miR-27a-3p (AUC = 0.72, CI95% = 0.59 to 0.85), miR-339-3p (AUC = 0.71, CI95% = 0.57 to 0.84), miR-144-3p (AUC = 0.70, CI95% = 0.56 to 0.83) and miR-326 (AUC = 0.69, CI95% = 0.56 to 0.82).
Fig 3
Fig 3. MicroRNA fold change in serum sample of heart transplant patients reported by time post-transplantation.
A) MiR-142-3p fold change and B) MiR-101-3p fold change (≤1 month, n = 14(NR) and n = 13(ACR); >1–3 months, n = 13(NR) and n = 6(ACR); >3–6 months, n = 7(NR) and n = 4(ACR); >6–12 months, n = 3(NR) and n = 3(ACR). All data are mean ±SEM, Student’s t-test, **p<0.01).
Fig 4
Fig 4. CRP level and microRNAs fold change in heart transplant patients.
(A) There is no significant difference between mean CRP level in acute cellular rejection group (n = 4) compared to the non-rejection group (n = 7) of heart transplant patients (NR = 32.2 mg/L vs. ACR = 3.5 mg/L, p = 0.1) and (B) There is no correlation between CRP level in heart transplant patients and miR-142-3p fold change (n = 11; R2 = 0.06 and P = 0.47) or miR-101-3p fold change (n = 11; R2 = 0.01 and P = 0.75).
Fig 5
Fig 5. Calcineurin inhibitor levels and microRNA fold change in heart transplant patients.
(A) There is no significant difference between mean tacrolimus level in acute cellular rejection group (n = 5) compared to the non-rejection group (n = 24) of heart transplant patients (NR = 12.9 ug/L vs. ACR = 10.4 ug/L, p = 0.4) and (B) There are no correlations between miR-142-3p fold change and tacrolimus (n = 29; R2 = 0.05; p = 0.25) or cyclosporin (n = 6; R2 = 0.07; p = 0.61) and there are no correlations between miR-101-3p fold change and tacrolimus (n = 29; R2 = 0.01; p = 0.10) or cyclosporine (n = 6; R2 = 0.05; p = 0.68).
Fig 6
Fig 6. Creatinine level and microRNAs fold change in heart transplant patients.
(A) There is no significant difference between mean creatinine level in ACR group (n = 26) vs. NR group (n = 37) in heart transplant patients (NR = 133.2 umol/L vs. ACR = 105.7 umol/L, p = 0.055). (B) There is no correlation between creatinine levels and miR-142-3p (R2 = 0.02, p = 0.24) or miR-101-3p (R2 = 0.06, p = 0.06) in heart transplant patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stehlik J, Starling RC, Movsesian MA, Fang JC, Brown RN, et al. (2006) Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant 25: 1402–1409. 10.1016/j.healun.2006.10.003 - DOI - PubMed
    1. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, et al. (2013) The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; focus theme: age. J Heart Lung Transplant 32: 951–964. 10.1016/j.healun.2013.08.006 - DOI - PubMed
    1. Winters GL, McManus BM (1996) Consistencies and controversies in the application of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. Rapamycin Cardiac Rejection Treatment Trial Pathologists. J Heart Lung Transplant 15: 728–735. - PubMed
    1. Nielsen H, Sorensen FB, Nielsen B, Bagger JP, Thayssen P, et al. (1993) Reproducibility of the acute rejection diagnosis in human cardiac allografts. The Stanford Classification and the International Grading System. J Heart Lung Transplant 12: 239–243. - PubMed
    1. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, et al. (2010) Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 362: 1890–1900. 10.1056/NEJMoa0912965 - DOI - PubMed

Publication types

MeSH terms

Grants and funding

This study was supported by The Swedish Heart and Lung Foundation (Grant Number: 20130543 to Dr. Jenny Öhman), Skåne University Hospital Funds, and the Foundations of Anna-Lisa and Sven-Eric Lundgren, Kocks, Crafoord, Lars-Erik Gelin, Lars Hierta and Tore Nilsson, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.